KLRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Kalaris Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$1.91−0.09 (-4.50%)
Close on Oct 19, 2026
- Market cap
- $45.45M
- P/E (TTM)
- –
- Dividend yield
- –
Fundamental chart
Pick a measure to chart its full history
-$46.15MFY2025